Brind.

Trinity Biotech's CGM+ aims to lower costs.

1 report, 1 independent Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Trinity Biotech's CGM+ aims to lower costs.

Who's involved

What this event is mainly about
DexcomBioTech

Keep exploring

The entities involved

  • Dexcom

    company that develops, manufactures and distributes continuous glucose monitoring systems

    Nothing else this week.

  • BioTech

    company in Prague, Czechia

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • ZacksTrinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data Trinity Biotech plc TRIB announced compelling positive clinical trial results with respect to its next-generation continuous gluco